Annotation Detail
Information
- Associated Genes
- BRAF
- Associated Variants
-
BRAF V600
BRAF V600 - Associated Disease
- melanoma
- Source Database
- CIViC Evidence
- Description
- Combination Dabrafenib and Trametinib treatment was assessed for adjuvant treatment of stage III resected BRAF V600 mutant melanoma in the COMBI-AD trial NCT01682083. Patients were treated with combination therapy or placebo for 12 months. The estimated 3-year rate of relapse-free survival was 58% in the treated group and 39% in the placebo group with hazard ratio for relapse or death of 0.47 (95% CI, 0.39 to 0.58; P<0.001). 3-year overall survival rate for treated group was 86%, and 77% in the placebo group (hazard ratio for death, 0.57; 95% CI, 0.42-0.79; P=0.0006). The level of improvement observed did not cross the prespecified interim analysis boundary of P=0.000019. Distant metastasis-free survival and freedom from relapse was higher in the combination-treated group.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/6180
- Gene URL
- https://civic.genome.wustl.edu/links/genes/5
- Variant URL
- https://civic.genome.wustl.edu/links/variants/17
- Rating
- 5
- Evidence Type
- Predictive
- Disease
- Melanoma
- Evidence Direction
- Supports
- Drug
- Trametinib,Dabrafenib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 28891408
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Dabrafenib | Sensitivity | true |
| Trametinib | Sensitivity | true |